STOCKHOLDERS' EQUITY (Tables)

9 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

Share-based Payment Arrangement, Option, Activity

Information with respect to option shares granted under all of our stock incentive plans for the nine months ended September 30, 2020 was as follows:

	Time-Based Shares	Performance-Based Shares	Total Shares	Weighted- Average Exercise Price	Weighted- Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (in thousands)
Options outstanding at January 1, 2020	565,000	—	565,000	$7.57
Granted	—	—	—	$—
Exercised	(175,355)	—	(175,355)	$7.73
Forfeited or canceled	—	—	—	$—
Options outstanding at September 30, 2020	389,645	—	389,645	$7.51	0.54	$413
Options vested at September 30, 2020 or expected to vest			389,645	$7.51	0.54	$413
Options exercisable at September 30, 2020			389,645	$7.51	0.54	$413

Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity

Information with respect to our non-vested restricted stock units for the nine months ended September 30, 2020 was as follows:

	Non-Vested Restricted Stock Units
	Time-Based Shares	Performance-Based Shares	Total Shares	Weighted- Average Grant-Date Fair Value	Weighted- Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (in thousands)
Non-vested at January 1, 2020	2,087,933	554,265	2,642,198	$6.40
Granted	1,424,480	578,316	2,002,796	$6.92
Vested	(991,552)	(328,673)	(1,320,225)	$6.23
Forfeited	(104,473)	—	(104,473)	$7.16
Non-vested at September 30, 2020	2,416,388	803,908	3,220,296	$6.77	1.03	$27,534
Expected to vest			3,220,296	$6.77	1.03	$27,534

Share-based Payment Arrangement, Expensed and Capitalized, Amount

Stock-based compensation was included in the following captions in our condensed consolidated statements of operations for the nine months ended September 30, 2020 and 2019 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Cost of products revenues	$	150	$	103	$	370	$	244
Cost of services revenues	283		82		539		177
Research and development expenses	546		305		1,199		762
Marketing and selling expenses	739		532		1,761		1,276
General and administrative expenses	1,579		1,023		4,263		3,329
	$	3,297	$	2,045	$	8,132	$	5,788